Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Feb. 13, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $127.50 to $7,830,617.50.

Highlighted Stocks Traded by Insiders:

HCA Holdings (HCA) - FREE Research Report

Vallarino Juan, who is SVP- Employer&Payer Engagement at HCA Holdings, sold 28,572 shares at $68.95 on Feb. 13, 2015. Following this transaction, the SVP- Employer&Payer Engagement owned 52,148 shares meaning that the stake was reduced by 35.4% with the 28,572-share transaction.

The shares most recently traded at $68.99, up $0.04, or 0.06% since the insider transaction. Historical insider transactions for HCA Holdings go as follows:

  • 4-Week # shares bought: 14,356
  • 4-Week # shares sold: 29,454
  • 12-Week # shares bought: 14,356
  • 12-Week # shares sold: 29,454
  • 24-Week # shares bought: 14,356
  • 24-Week # shares sold: 29,454

The average volume for HCA Holdings has been 5.0 million shares per day over the past 30 days. HCA Holdings has a market cap of $29.7 billion and is part of the health care sector and health services industry. Shares are down 6.61% year-to-date as of the close of trading on Friday.

HCA Holdings, Inc., through its subsidiaries, provides health care services. The company has a P/E ratio of 14.6. Currently, there are 16 analysts who rate HCA Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HCA - FREE

TheStreet Quant Ratings rates HCA Holdings as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, revenue growth, good cash flow from operations and compelling growth in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full HCA Holdings Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Foundation Medicine (FMI) - FREE Research Report

Pellini Michael J, who is President & CEO at Foundation Medicine, sold 17,500 shares at $48.56 on Feb. 13, 2015. Following this transaction, the President & CEO owned 420,000 shares meaning that the stake was reduced by 4% with the 17,500-share transaction.

The shares most recently traded at $48.86, up $0.30, or 0.61% since the insider transaction. Historical insider transactions for Foundation Medicine go as follows:

  • 4-Week # shares sold: 17,500
  • 12-Week # shares sold: 65,921
  • 24-Week # shares sold: 95,412

The average volume for Foundation Medicine has been 478,900 shares per day over the past 30 days. Foundation Medicine has a market cap of $1.4 billion and is part of the health care sector and health services industry. Shares are up 119.98% year-to-date as of the close of trading on Friday.

Foundation Medicine, Inc. provides various molecular information products in the United States. The company has a P/E ratio of 14.1. Currently, there are 3 analysts who rate Foundation Medicine a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FMI - FREE

TheStreet Quant Ratings rates Foundation Medicine as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share. Get the full Foundation Medicine Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cardiovascular Systems (CSII) - FREE Research Report

Betterley Laurence L, who is Chief Financial Officer at Cardiovascular Systems, sold 10,211 shares at $36.25 on Feb. 13, 2015. Following this transaction, the Chief Financial Officer owned 173,500 shares meaning that the stake was reduced by 5.56% with the 10,211-share transaction.

The shares most recently traded at $35.65, down $0.60, or 1.7% since the insider transaction. Historical insider transactions for Cardiovascular Systems go as follows:

  • 4-Week # shares sold: 38,248
  • 12-Week # shares sold: 38,248
  • 24-Week # shares bought: 10,250
  • 24-Week # shares sold: 68,786

The average volume for Cardiovascular Systems has been 228,500 shares per day over the past 30 days. Cardiovascular Systems has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are up 18.65% year-to-date as of the close of trading on Friday.

Cardiovascular Systems, Inc., a medical device company, focuses on developing and commercializing minimally invasive treatment solutions for vascular diseases. Currently, there are 7 analysts who rate Cardiovascular Systems a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CSII - FREE

TheStreet Quant Ratings rates Cardiovascular Systems as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full Cardiovascular Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null